1 / 22

Our Locations in Europe

Our Locations in Europe. Headquarters Affiliates Plant sites. Dublin. London. Amsterdam. Brussels. Pfaffenhofen. Paris. Altkirch. Vienna. Munich. Zurich. Madrid. Rome. Lisbon. Istanbul. European Production Sites. Altkirch , France. Pfaffenhofen, Germany.

lola
Download Presentation

Our Locations in Europe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Our Locations in Europe Headquarters Affiliates Plant sites Dublin London Amsterdam Brussels Pfaffenhofen Paris Altkirch Vienna Munich Zurich Madrid Rome Lisbon Istanbul

  2. European Production Sites Altkirch, France Pfaffenhofen, Germany

  3. Facts and Figures of Our Pfaffenhofen Plant • Pharmaceutical manufacturing activities established at the current site as part of Luitpold-Werk in 1962 • Additional state-of-the-art facilities for solids manufacturing/packaging inaugurated in 2007 • Only DAIICHI SANKYO plant in Europe producing bulk and finished pharmaceutical goods • Approved by local and international authorities such as the U.S. FDA • Approximately 70 per cent of DAIICHI SANKYO EUROPE’s turnover is produced or handled via the Pfaffenhofen plant • Toll manufacturing for USA and Asian markets • Successful development and launch site for new products, such as OLMETEC PLUS®, SEVIKAR®/AZOR®, and CS-8635

  4. Sales of Global Products Exchange rates: (FY 2008) ¥143.5=€1 / (FY 2009) ¥131.2=€1 These figures do not include out-licensing sales.

  5. Main Products in Europe

  6. EFIENT® Potential blockbuster in cardiovascular care Antiplatelet agent to prevent atherothrombotic events Discovered by DAIICHI SANKYO and its Japanese research partner Ube Industries, co-developed and co-promoted with Eli Lilly and Company European launch sequence started in Spring 2009 Key contributor to company sales over the next years

  7. The Olmesartan Success Story Leading angiotensin receptor blocker (ARB) with excellent blood pressure lowering efficacy Launched in 2002 as 7th product in the ARB market, still showing high growth rates OLMETEC® launched in 58 countries worldwide*, including the majority of European markets Co-marketing agreements with Menarini Group, Pfizer, Nycomed OLMETEC PLUS® launched in majority of European countries, launch sequence for additionaldosage comprising 40 milligrams olmesartan startedin Spring 2010 SEVIKAR® launched in several European countriesin 2009 Singel pill combination containing olmesartan, hydrochlorotiazide and amlodipine in approval process *As of February 2010

  8. SEVIKAR® Fixed dose combination of olmesartan and amlodipine Significantly lowers blood pressure and was well tolerated in clinical trials Effective treatment option: Most hypertensive patients need two or more medications to normalise their blood pressure Approval for majority of European countries achieved, launch started in January 2009 In the U.S. the combination was already approved in September 2007 under the name of AZOR®, sales have been successful since launch in October 2007

  9. EVISTA®

  10. R&D Expenditures in the Fiscal Year 2009 €1.5 billion 20.7% of net sales Creating first-in-class, best-in-class, high-value-added products KazunoriHirokawa Head of R&D Division DAIICHI SANKYO EUROPE GmbH

  11. DAIICHI SANKYO is Investing Heavily into R&D Percentage of net sales 21.9% 21.4% 20.7% 18.5% 18.3% * Forecast

  12. R&D Today: Overview

  13. The Global R&D Network DAIICHI SANKYO R&D ~ 1,500 people Pharmaceuticaltechnology ~400 People AsubioPharma ~ 300 people DAIICHI SANKYO RD Associe ~150 people DAIICHI SANKYO DEVELOPMENT (London) ~ 50 people DAIICHI SANKYO (Edison, NJ) ~300 people Luitpold Pharmaceuticals (Shirley, NY) ~40 people DAIICHI SANKYO EUROPE (Munich) ~130 people U3 Pharma (Munich) ~28 people Asia, South & Central America ~80 people Ranbaxy Laboratories ~1,400 people As of 31 March 2010

  14. The European R&D Network DAIICHI SANKYOEUROPE GmbH Munich 130 people(development, pharmaceuticaltechnology) DAIICHI SANKYODEVELOPMENT LTD.London 50 people(development) U3 Pharma GmbH Martinsried 28 people (research) As of 31 March 2010

  15. R&D Highlights • Invention of the statin class • Invention of insulin sensitizer class (TZDs) • Invention of the oral factor Xa class • Leading quinolones (levofloxacin, ofloxacin) • Best-in-class angiotensin II receptor blocker (olmesartan) • Standard colon cancer treatment developed (irinotecan) DAIICHI SANKYO invents and develops globally leading products

  16. Our R&D Focus

  17. Cardiovascular Pipeline

  18. Development of Factor Xa Inhibitor Edoxaban Edoxaban is a direct factor Xa inhibitor and a member of a new class of oral anticoagulants. It is given once daily and has been investigated in phase II trials in patients undergoing orthopedic surgery and in patients with atrial fibrillation. It is developed solely by DAIICHI SANKYO as a new treatment for the prevention of both arterial and venous thromboembolism. Edoxaban is tested in two phase III clinical studies ENGAGE AF-TIMI 48 with about 16,500 patients focuses on prevention of thromboembolic stroke in atrial fibrillation. HOKUSAI-VTE with about 7,500 patients focuses on the treatment and recurrence-prevention of venous thromboembolism.

  19. Oncology Pipeline

  20. Key Projects fromour Development Pipeline *Only developed in Japan / **Only developed in the US / As of March 2010

  21. Acknowledged Research Pipeline • Renowned R&D Directions magazine selected DAIICHI SANKYO in 2009 to have the “Best Cardiovascular Pipeline” • Great potential of EFIENT® and edoxaban acknowledged • More than 25 years experience with anticoagulants and anti-thrombotics

  22. Major Group Companies

More Related